The #ENDO3trial is a big step towards generating evidence in surgical treatment of endometrial cancer. It is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection.
The outcomes from this world-first trial will provide high-level evidence on sentinel lymph node dissection’s effectiveness, benefit and harm to patients and will determine the value of retaining or discontinuing this procedure in the treatment of apparent early stage endometrial cancer.
The trial now has five recruitment sites in Queensland and 46 patients involved. In 2022, sites throughout Australia, Europe, South America, Asia and the United States will join the trial. Over the next three years, researchers aim to recruit 760 trial volunteers. Ultimately, ENDO-3 will help shape the surgical treatment of endometrial cancer in the future.
Listen to this recent podcast, as Cherish founder Professor Andreas Obermair speaks about ENDO-3 with the International Journal of Gynecological Cancer (IJGC) Editor-in-Chief Professor Pedro Ramirez.
